Skip to main
ROIV
ROIV logo

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd demonstrates a strong outlook due to the commercial potential of its drug candidates, particularly brepocitinib, which offers a significant therapeutic advancement in comparison to existing treatments for dermatomyositis (DM). The drug's convenient once-daily dosing provides a competitive edge over the current therapy, IVIg, which generates approximately $500 million in global sales but requires cumbersome infusion sessions. Additionally, brepocitinib's clinical results, including a notable mean total improvement score (TIS) of 46.5, underpin its efficacy and could enhance market confidence and investor interest in Roivant Sciences's portfolio.

Bears say

Roivant Sciences Ltd has experienced significant setbacks in its clinical development pipeline, including the failures of crucial assets such as IMVT and brepocitinib in various trials, which undermines investor confidence in its future growth prospects. The repeated failures highlight the risks associated with its reliance on a narrow range of developmental candidates, placing increased pressure on the success of VTAMA as its sole commercialized product. These factors raise concerns regarding the company's ability to achieve sustainable revenue generation, thereby contributing to a negative outlook on its stock performance.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.